Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 937

1.

Vertical blockade of the IGFR- PI3K/Akt/mTOR pathway for the treatment of hepatocellular carcinoma: the role of survivin.

Ou DL, Lee BS, Lin LI, Liou JY, Liao SC, Hsu C, Cheng AL.

Mol Cancer. 2014 Jan 3;13:2. doi: 10.1186/1476-4598-13-2.

2.

Potentiating the efficacy of molecular targeted therapy for hepatocellular carcinoma by inhibiting the insulin-like growth factor pathway.

Ou DL, Lee BS, Chang YC, Lin LI, Liou JY, Hsu C, Cheng AL.

PLoS One. 2013 Jun 20;8(6):e66589. doi: 10.1371/journal.pone.0066589.

3.

Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.

Zhou Q, Lui VW, Lau CP, Cheng SH, Ng MH, Cai Y, Chan SL, Yeo W.

Biochem Pharmacol. 2012 May 1;83(9):1146-58. doi: 10.1016/j.bcp.2012.01.013.

PMID:
22285225
4.

Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells.

Grabinski N, Ewald F, Hofmann BT, Staufer K, Schumacher U, Nashan B, Jücker M.

Mol Cancer. 2012 Nov 20;11:85. doi: 10.1186/1476-4598-11-85.

5.
6.

HS-116, a novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and suppresses angiogenesis of hepatocellular carcinoma through inhibition of the PI3K/AKT/mTOR pathway.

Jung KH, Choi MJ, Hong S, Lee H, Hong SW, Zheng HM, Lee HS, Hong S, Hong SS.

Cancer Lett. 2012 Mar 28;316(2):187-95. doi: 10.1016/j.canlet.2011.10.037.

PMID:
22182943
7.

Dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 has a therapeutic potential and sensitizes cisplatin in nasopharyngeal carcinoma.

Yang F, Qian XJ, Qin W, Deng R, Wu XQ, Qin J, Feng GK, Zhu XF.

PLoS One. 2013;8(3):e59879. doi: 10.1371/journal.pone.0059879.

8.

Dual PI3K/mTOR inhibitor NVP-BEZ235-induced apoptosis of hepatocellular carcinoma cell lines is enhanced by inhibitors of autophagy.

Chang Z, Shi G, Jin J, Guo H, Guo X, Luo F, Song Y, Jia X.

Int J Mol Med. 2013 Jun;31(6):1449-56. doi: 10.3892/ijmm.2013.1351.

PMID:
23588698
9.

Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model.

Wang C, Gao D, Guo K, Kang X, Jiang K, Sun C, Li Y, Sun L, Shu H, Jin G, Sun H, Wu W, Liu Y.

BMC Cancer. 2012 May 4;12:166. doi: 10.1186/1471-2407-12-166.

10.

Growth inhibition by NVP-BEZ235, a dual PI3K/mTOR inhibitor, in hepatocellular carcinoma cell lines.

Masuda M, Shimomura M, Kobayashi K, Kojima S, Nakatsura T.

Oncol Rep. 2011 Nov;26(5):1273-9. doi: 10.3892/or.2011.1370.

PMID:
21725613
11.

SB365 inhibits angiogenesis and induces apoptosis of hepatocellular carcinoma through modulation of PI3K/Akt/mTOR signaling pathway.

Hong SW, Jung KH, Lee HS, Choi MJ, Son MK, Zheng HM, Hong SS.

Cancer Sci. 2012 Nov;103(11):1929-37. doi: 10.1111/j.1349-7006.2012.02409.x. Erratum in: Cancer Sci. 2013 Oct;104(10):1389.

12.

Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.

Shoji K, Oda K, Kashiyama T, Ikeda Y, Nakagawa S, Sone K, Miyamoto Y, Hiraike H, Tanikawa M, Miyasaka A, Koso T, Matsumoto Y, Wada-Hiraike O, Kawana K, Kuramoto H, McCormick F, Aburatani H, Yano T, Kozuma S, Taketani Y.

PLoS One. 2012;7(5):e37431. doi: 10.1371/journal.pone.0037431.

13.

Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma.

Chan SL, Wong CH, Lau CP, Zhou Q, Hui CW, Lui VW, Ma BB, Chan AT, Yeo W.

Cancer Chemother Pharmacol. 2013 Jun;71(6):1417-25. doi: 10.1007/s00280-013-2139-4.

PMID:
23546591
15.

Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition.

Charette N, De Saeger C, Lannoy V, Horsmans Y, Leclercq I, Stärkel P.

Mol Cancer. 2010 Sep 22;9:256. doi: 10.1186/1476-4598-9-256.

16.

Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease.

Zitzmann K, Rüden Jv, Brand S, Göke B, Lichtl J, Spöttl G, Auernhammer CJ.

Cancer Lett. 2010 Sep 1;295(1):100-9. doi: 10.1016/j.canlet.2010.02.018.

PMID:
20356670
17.

Inhibition of autophagy enhances apoptosis induced by the PI3K/AKT/mTor inhibitor NVP-BEZ235 in renal cell carcinoma cells.

Li H, Jin X, Zhang Z, Xing Y, Kong X.

Cell Biochem Funct. 2013 Jul;31(5):427-33. doi: 10.1002/cbf.2917.

PMID:
23086777
18.

NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.

Yu Z, Xie G, Zhou G, Cheng Y, Zhang G, Yao G, Chen Y, Li Y, Zhao G.

Cancer Lett. 2015 Oct 10;367(1):58-68. doi: 10.1016/j.canlet.2015.07.007.

PMID:
26188279
19.

Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells.

Höpfner M, Huether A, Sutter AP, Baradari V, Schuppan D, Scherübl H.

Biochem Pharmacol. 2006 May 14;71(10):1435-48.

PMID:
16530734
20.

Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation.

Okabe S, Tauchi T, Tanaka Y, Kitahara T, Kimura S, Maekawa T, Ohyashiki K.

Cancer Biol Ther. 2014 Feb;15(2):207-15. doi: 10.4161/cbt.26725.

Supplemental Content

Support Center